Betablockers for Glaucoma Do Not Increase Parkinson’s Risk – Study Finds

Topical beta-blockers used to treat glaucoma do not increase the risk of developing Parkinson’s disease, according to a new study published in the British Journal of Ophthalmology. The findings offer reassurance to patients and clinicians who have previously questioned whether this common glaucoma treatment might contribute to neurodegenerative risk.

The retrospective cohort study analyzed data from all newly diagnosed glaucoma patients between 2000 and 2020, comparing those treated with topical beta-blockers to those who were not. Researchers found no significant association between the use of these eye drops and a later diagnosis of Parkinson’s disease.

“Topical beta-blocker use was not associated with an increased risk of PD,” the study authors concluded. “These findings suggest that topical beta-blockers are a safe therapeutic option, even for patients at potential risk for Parkinson’s disease.”

Addressing Long-Standing Concerns About Beta-Blockers and Neurodegeneration

Concerns about a possible link between beta-blockers and Parkinson’s disease have persisted for years, primarily stemming from observations about systemic beta-blockers — medications taken orally or by injection that affect the entire body. Some earlier research had suggested that systemic use might interfere with neurological pathways involved in motor control, potentially increasing vulnerability to Parkinson’s.

However, topical beta-blockers, which are applied directly to the eye to reduce intraocular pressure in glaucoma patients, work locally and have minimal systemic absorption. This distinction has been critical in evaluating their safety profile.

The current study specifically aimed to isolate the effects of topical administration, minimizing confounding factors from oral medications. By focusing exclusively on eye drop formulations, researchers were able to assess whether the localized use of these drugs carries any Parkinson’s-related risk.

Consistent Findings Across Multiple Studies

These results align with earlier research, including a 2020 study published in PubMed Central, which also found no increased risk of Parkinson’s disease associated with topical beta-blocker use in glaucoma patients. That study similarly emphasized the safety of this class of medication for long-term ocular management.

Additional support comes from analyses by the American Parkinson Disease Association, which has reviewed prescription trends and found no consistent evidence that beta-blockers — whether topical or systemic — significantly elevate Parkinson’s risk in the general population when used as prescribed.

While systemic beta-blockers continue to be studied for their neurological effects, the weight of current evidence indicates that topical formulations used in ophthalmology do not share the same concerns.

Implications for Glaucoma Management

Glaucoma is a leading cause of irreversible blindness worldwide, affecting over 80 million people. Beta-blockers such as timolol have been a cornerstone of glaucoma treatment for decades due to their effectiveness in lowering eye pressure and preventing optic nerve damage.

For patients who require long-term therapy — particularly older adults who may already be at higher age-related risk for Parkinson’s disease — the confirmation that topical beta-blockers do not add to that risk is clinically meaningful. It allows clinicians to continue prescribing these medications without hesitation based on neurodegeneration fears.

The study also notes that preservative-free formulations of topical beta-blockers have shown comparable efficacy to preserved versions, offering additional options for patients with ocular surface sensitivity.

Ongoing Vigilance in Medication Safety

Researchers acknowledge that while this study provides strong reassurance, ongoing monitoring of medication safety remains essential. Long-term registries and real-world evidence studies continue to play a vital role in detecting rare or delayed adverse effects that may not emerge in shorter trials.

Future research may explore whether specific subtypes of glaucoma patients or those with genetic predispositions to Parkinson’s disease respond differently to various treatments — though current data do not suggest a need to alter prescribing practices based on Parkinson’s risk alone.

For now, the message to patients is clear: using topical beta-blocker eye drops as prescribed for glaucoma does not appear to increase the likelihood of developing Parkinson’s disease.